Literature DB >> 16885052

Methodological approach to minimal residual disease detection by flow cytometry in adult B-lineage acute lymphoblastic leukemia.

Mauro Krampera1, Omar Perbellini, Carlo Vincenzi, Francesca Zampieri, Annalisa Pasini, Maria Teresa Scupoli, Anna Guarini, Maria Stefania De Propris, Elaine Coustan-Smith, Dario Campana, Robin Foà, Giovanni Pizzolo.   

Abstract

A flow cytometric approach to minimal residual disease (MRD) monitoring useful in childhood B-lineage acute lymphoblastic leukemia (ALL) is discussed here in the context of ALL in adults. Of 64 leukemia samples analyzed, 95.3% had at least one abnormal phenotype (57.3% had two or more) as compared to physiologic B-cell precursors in adult bone marrow. The method was sensitive enough to detect one leukemic cell among 10,000 normal cells in 16/19 experiments (84.2%). Blast phenotypes were stable in culture and at relapse, and were useful for MRD monitoring in patients. Marker combinations for childhood ALL are also applicable to adult cases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16885052

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  11 in total

1.  Enhanced sensitivity of flow cytometry for routine assessment of minimal residual disease.

Authors:  Esther Domingo; Cristina Moreno; Alfonso Sánchez-Ibarrola; Carlos Panizo; José Antonio Páramo; Juana Merino
Journal:  Haematologica       Date:  2009-11-30       Impact factor: 9.941

2.  BCR-ABL1 and CD66c exhibit high concordance in minimal residual disease detection of adult B-acute lymphoblastic leukemia.

Authors:  Gu-Sheng Tang; Jun Wu; Min Liu; Hui Chen; Shen-Glan Gong; Jian-Min Yang; Xiao-Xia Hu; Jian-Min Wang
Journal:  Am J Transl Res       Date:  2015-03-15       Impact factor: 4.060

Review 3.  Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies.

Authors:  Jacques J M van Dongen; Vincent H J van der Velden; Monika Brüggemann; Alberto Orfao
Journal:  Blood       Date:  2015-05-21       Impact factor: 22.113

4.  Critical evaluation of the utility of pre- and post-therapy immunophenotypes in assessment of measurable residual disease in B-ALL.

Authors:  Nupur Das; Ritu Gupta; Sanjeev Kumar Gupta; Sameer Bakhshi; Rachna Seth; Chandan Kumar; Sandeep Rai; Saroj Singh; Vijay Kumar Prajapati; Ajay Gogia; Ranjit Kumar Sahoo; Atul Sharma; Lalit Kumar
Journal:  Ann Hematol       Date:  2021-07-08       Impact factor: 3.673

Review 5.  Immunologic minimal residual disease detection in acute lymphoblastic leukemia: a comparative approach to molecular testing.

Authors:  Elaine Coustan-Smith; Dario Campana
Journal:  Best Pract Res Clin Haematol       Date:  2010-10-28       Impact factor: 3.020

6.  Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation.

Authors:  Yiming Chen; Jorge Cortes; Zeev Estrov; Stefan Faderl; Wei Qiao; Lynne Abruzzo; Guillermo Garcia-Manero; Sherry Pierce; Xuelin Huang; Partow Kebriaei; Tapan Kadia; Marcos De Lima; Hagop Kantarjian; Farhad Ravandi
Journal:  J Clin Oncol       Date:  2011-05-09       Impact factor: 44.544

Review 7.  Right on target: eradicating leukemic stem cells.

Authors:  Daniela S Krause; Richard A Van Etten
Journal:  Trends Mol Med       Date:  2007-11-05       Impact factor: 11.951

8.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.

Authors:  Michael J Borowitz; Meenakshi Devidas; Stephen P Hunger; W Paul Bowman; Andrew J Carroll; William L Carroll; Stephen Linda; Paul L Martin; D Jeanette Pullen; David Viswanatha; Cheryl L Willman; Naomi Winick; Bruce M Camitta
Journal:  Blood       Date:  2008-04-03       Impact factor: 22.113

9.  Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting.

Authors:  Julie Irving; Jenny Jesson; Paul Virgo; Marian Case; Lynne Minto; Lisa Eyre; Nigel Noel; Ulrika Johansson; Marion Macey; Linda Knotts; Margaret Helliwell; Paul Davies; Liam Whitby; David Barnett; Jeremy Hancock; Nick Goulden; Sarah Lawson
Journal:  Haematologica       Date:  2009-04-18       Impact factor: 9.941

Review 10.  Minimal residual disease in acute lymphoblastic leukemia: optimal methods and clinical relevance, pitfalls and recent approaches.

Authors:  Fatemeh Salari; Mohammad Shahjahani; Saeid Shahrabi; Najmaldin Saki
Journal:  Med Oncol       Date:  2014-10-07       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.